Skip to main content
SpringerLink
Log in

The Clinical Utility of Bevacizumab

  • Chapter
Angiogenesis

Targeting angiogenesis is a rapidly emerging field of cancer research. Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that is at the forefront of clinical investigations and is FDA-approved for several neoplasms, including advanced colon, lung, and renal cancers. This chapter discusses key clinical trials that led to the approval of bevacizumab, its promising use in a variety of other cancers such as ovarian, prostate and breast cancer, as well as safety and toxicity monitoring in the use of bevacizumab.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;7(1):53–64.

    Article  PubMed  CAS  Google Scholar 

  2. Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57(20):4593–9.

    PubMed  CAS  Google Scholar 

  3. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001;19(3):851–6.

    PubMed  CAS  Google Scholar 

  4. Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999;288(1):371–8.

    PubMed  CAS  Google Scholar 

  5. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56(17):4032–9.

    PubMed  CAS  Google Scholar 

  6. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841–4.

    Article  PubMed  CAS  Google Scholar 

  7. Panares RL, Garcia AA. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 2007;7(4):433–45.

    Article  PubMed  CAS  Google Scholar 

  8. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3(5):391–400.

    Article  PubMed  CAS  Google Scholar 

  9. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182–6.

    PubMed  CAS  Google Scholar 

  10. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15–8.

    PubMed  CAS  Google Scholar 

  11. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84(24):1875–87.

    Article  PubMed  CAS  Google Scholar 

  12. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143(2):401–9.

    PubMed  CAS  Google Scholar 

  13. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 1991;324(1):1–8.

    PubMed  CAS  Google Scholar 

  14. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65(3):671–80.

    PubMed  CAS  Google Scholar 

  15. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95(4):1789–97.

    Article  PubMed  CAS  Google Scholar 

  16. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669–76.

    Article  PubMed  CAS  Google Scholar 

  17. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58–62.

    Article  PubMed  CAS  Google Scholar 

  18. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24–40.

    Article  PubMed  CAS  Google Scholar 

  19. Lee TH, Avraham HK, Jiang S, Avraham S. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem 2003;278(7):5277–84.

    Article  PubMed  CAS  Google Scholar 

  20. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88(12):1979–86.

    Article  PubMed  CAS  Google Scholar 

  21. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64(11):3731–6.

    Article  PubMed  CAS  Google Scholar 

  22. Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60(19):5565–70.

    PubMed  CAS  Google Scholar 

  23. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19(3):843–50.

    PubMed  CAS  Google Scholar 

  24. Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 2007;32(1):1–14.

    Article  PubMed  CAS  Google Scholar 

  25. Genentech. US prescribing information. In: South San Francisco, CA: Genentech Inc.; 2005.

    Google Scholar 

  26. Gaudreault J, Bruno R, Kabbinavar F, Sing A, Johnson DH, Lu J. Clinical pharmacokinetics of bevacizumab following every 2- or every 3-week dosing. J Clin Oncol (Meeting Abstracts) 2004;22(14_suppl):3041.

    Google Scholar 

  27. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60–5.

    Article  PubMed  CAS  Google Scholar 

  28. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184–91.

    Article  PubMed  CAS  Google Scholar 

  29. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427–34.

    Article  PubMed  CAS  Google Scholar 

  30. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117–24.

    Article  PubMed  CAS  Google Scholar 

  31. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. Oncologist 2004;9 Suppl 1:36–42.

    Article  PubMed  CAS  Google Scholar 

  32. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43–66.

    Article  PubMed  Google Scholar 

  33. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Bmj 1993;306(6880):752–5.

    Article  PubMed  CAS  Google Scholar 

  34. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1992;10(6):904–11.

    Google Scholar 

  35. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Bmj 2000;321(7260):531–5.

    Article  PubMed  CAS  Google Scholar 

  36. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22(18):3766–75.

    Article  PubMed  CAS  Google Scholar 

  37. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343(13):905–14.

    Article  PubMed  CAS  Google Scholar 

  38. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355(9209):1041–7.

    Article  PubMed  CAS  Google Scholar 

  39. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938–47.

    PubMed  Google Scholar 

  40. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335–42.

    Article  PubMed  CAS  Google Scholar 

  41. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23(15):3502–8.

    Article  PubMed  CAS  Google Scholar 

  42. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23(16):3697–705.

    Article  PubMed  CAS  Google Scholar 

  43. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23(16):3706–12.

    Article  PubMed  CAS  Google Scholar 

  44. Giantonio BJ, Levy DE, O’Dwyer P J, Meropol NJ, Catalano PJ, Benson AB, 3rd. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006;17(9):1399–403.

    Article  PubMed  CAS  Google Scholar 

  45. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23–30.

    Article  PubMed  CAS  Google Scholar 

  46. Thomas M, Hoff P, Wolff R. The MD Anderson Manual of Medical Oncology. New York: McGraw-Hill; 2006.

    Google Scholar 

  47. Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 2007;7:91.

    Article  PubMed  CAS  Google Scholar 

  48. Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. J Clin Oncol (Meeting Abstracts) 2006;24(18_suppl):3510.

    Google Scholar 

  49. Bevacizumab (Avastin) Drug Label. (Accessed August 15, 2007, at http://www.fda.gov/cder/drug/infopage/avastin/default.htm.).

  50. NCCN. National Comprehensive Cancer Network (NCCN) Practice Guidelines version 2.2007. In: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf; Accessed on August 11, 2007.

  51. Ellenhorn J, Cullinane C, Coia L, Alberts SR. Cancer Management: A Multidisciplinay Approach. 10th ed. Lawrence, KS: CMP Medica; 2007.

    Google Scholar 

  52. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539–44.

    Article  PubMed  CAS  Google Scholar 

  53. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007;12(3):356–61.

    Article  PubMed  CAS  Google Scholar 

  54. Saltz LB, Lenz HJ, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol (Meeting Abstracts) 2005;23(16_suppl):3508.

    Google Scholar 

  55. Emmanouilides C, Pegram M, Robinson R, Hecht R, Kabbinavar F, Isacoff W. Anti-VEGF antibody bevacizumab (Avastin) with 5 FU/LV as third line treatment for colorectal cancer. Tech Coloproctol 2004;8 Suppl 1:s50–2.

    Article  PubMed  Google Scholar 

  56. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7(10):1447–56.

    PubMed  CAS  Google Scholar 

  57. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322(6):352–8.

    Article  PubMed  CAS  Google Scholar 

  58. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122(5):321–6.

    PubMed  CAS  Google Scholar 

  59. O’Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15(1):246–50.

    PubMed  Google Scholar 

  60. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11(10):1879–87.

    PubMed  CAS  Google Scholar 

  61. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343–51.

    Article  PubMed  CAS  Google Scholar 

  62. Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25(16):2198–204.

    Article  PubMed  CAS  Google Scholar 

  63. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007;57(3):168–85.

    Article  PubMed  Google Scholar 

  64. NCT00112918. http://clinicaltrials.gov/ct/show/NCT00112918 Accessed on August 11, 2007.

  65. NCT00217737. http://clinicaltrials.gov/ct/show/NCT00217737. Accessed on August 11, 2007.

  66. NCT00096278. http://clinicaltrials.gov/ct/show/NCT00096278. Accessed on August 11, 2007.

  67. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24(28):4539–44.

    Article  PubMed  Google Scholar 

  68. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92–8.

    Article  PubMed  CAS  Google Scholar 

  69. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. Jama 2004;292(4):470–84.

    Article  PubMed  CAS  Google Scholar 

  70. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3(2):65–71.

    PubMed  CAS  Google Scholar 

  71. Fontanini G, Bigini D, Vignati S, et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995;177(1):57–63.

    Article  PubMed  CAS  Google Scholar 

  72. Lucchi M, Fontanini G, Mussi A, et al. Tumor angiogenesis and biologic markers in resected stage I NSCLC. Eur J Cardiothorac Surg 1997;12(4):535–41.

    Article  PubMed  CAS  Google Scholar 

  73. D’Amico TA, Massey M, Herndon JE, 2nd, Moore MB, Harpole DH, Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999;117(4):736–43.

    Article  PubMed  Google Scholar 

  74. Ushijima C, Tsukamoto S, Yamazaki K, Yoshino I, Sugio K, Sugimachi K. High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. Lung Cancer 2001;34(2):233–41.

    Article  PubMed  CAS  Google Scholar 

  75. Sledge GW, Jr., Miller KD. Angiogenesis and antiangiogenic therapy. Curr Probl Cancer 2002;26(1):1–60.

    PubMed  Google Scholar 

  76. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542–50.

    Article  PubMed  CAS  Google Scholar 

  77. FDA Approves New Combination Therapy for Lung Cancer. (Accessed August 11, 2007, at http://www.fda.gov/bbs/topics/news/2006/new01488.html.).

  78. Manegold C, von Pawel, J, Zatloukal, P, Ramlau, R, Gorbounova, V, Hirsh, V, Leighl, N, Mezger, J, Archer, V, Reck M. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Onc 25 (18 S), 2007: LBA7514.

    Google Scholar 

  79. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23(11):2544–55.

    Article  PubMed  CAS  Google Scholar 

  80. Fehrenbacher L, O’Neill, V., Belani, CP et al. A Phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy of (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for the treatment of recurrent or refractory non-small cell lung cancer. In: 42nd ASCO Annual Meeting; 2006; 2006.

    Google Scholar 

  81. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792–9.

    Article  PubMed  CAS  Google Scholar 

  82. Miller K, Wang, M., Gralow, J. et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab plus paclitaxel as first line therapy for recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). In: 28th Annual San Antonio Breast Cancer Symposium, San Antonio (TX): Breast Cancer Research and Treatment December, 2005.

    Google Scholar 

  83. NCCN Practice Guidelines in Oncology, Breast Cancer, V.2.2007. (Accessed August 11, 2007, at http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.).

  84. Burstein H, Parker L, Savoie, J Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advamced breast cancer. Breast Cancer Res Treat 2002;76:2115:446.

    Google Scholar 

  85. Ramaswamy B, Elias AD, Kelbick NT, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006;12(10):3124–9.

    Article  PubMed  CAS  Google Scholar 

  86. Link J, Waisman, JR, Nguyen, B, Jacobs, CI. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. J Clin Onc, Vol 25, No 18 S, 2007: 1101;.

    Google Scholar 

  87. Traina TA, Rugo HS, Dickler M. Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 2007;21(2):303–19.

    Article  PubMed  Google Scholar 

  88. Traina T, Rugo, H, Caravelli, J, Yeh, B, Panageas, K, Bruckner, J, Norton, L, Park, J, Hudis, C, Dickler, M. Letrozole with bevacizumab is feasible in patients with hormone receptor- positive metastatic breast cancer J Clin Onc, 24 (18 S), 2006: 3050.

    Google Scholar 

  89. Forero-Torres A, Percent, I, Galleshaw, J, Nabell, L, Carpenter, J, Falkson, C, Jones, C, Krontriras, H, De Los Santos, J, Saleh, M A study of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed operable breast cancer: A preliminary safety report. J of Clin Onc 25(18 S), 2007: 11020.

    Google Scholar 

  90. Mayer E, Miller, KD, Rugo, HS, Peppercorn, JM, Carey, LA, Ryabin, N, Winer, EP, Burstein, HJ. A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer. J of Clin Onc 25(18 S), 2007: 561.

    Google Scholar 

  91. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007;25(20): 2902–8.

    Article  PubMed  CAS  Google Scholar 

  92. Burger R, Sill, M, Monk, BJ, Greer, B., Sorosk, J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Onc 23(16 S) 2005: 5009.

    Google Scholar 

  93. Cannistra S, Matulonis, U, Penson, R, Wenham, R, Armstrong, D, Burger, RA, Mackey, H, Douglas, J, Hambleton, J, McGuire, W. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Onc 24(18 S) 2005: 5006.

    Google Scholar 

  94. Azad N, Posadas, EM, Kwitkowski, VE, Annunziata, CM, Barrett, T, Premkumar, A, Kotz, HL, Sarosy, GA, Minasian, LM, Kohn, EC. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. J Clin Onc 24(18 S) 2006: 3004.

    Google Scholar 

  95. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17(9):5629–39.

    PubMed  CAS  Google Scholar 

  96. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996;93(20):10589–94.

    Article  PubMed  CAS  Google Scholar 

  97. Escudier B, Koralewski, P, Pluzanska, A. Ravaud, A, Bracarda, S, Szczylik, C, Chevreau, C, Filipek, M, Melichar, B, Moore, N. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Onc 25(18 S) 2007: 3.

    Google Scholar 

  98. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12.

    Article  PubMed  CAS  Google Scholar 

  99. Picus J, Halabi, S, Rini, B, Vogelzang, N, Whang, Y, Kaplan, E, Kelly, W, Small, E. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: Initial results of CALGB 90006. Proc Am Soc Clin Oncol 22: 2003 (abstr 1578).

    Google Scholar 

  100. Ning Y, Arlen, P, Gulley, J, Latham, L, Jones, E, Chen, C, Parnes, H, Wright, J, Figg, WD, Dahut, WL. A phase II trial of thalidomide, bevacizumab, and docetaxel in patients with metastatic androgen-independent prostate cancer. J Clin Onc 25(16 S) 2007: 5114;.

    Google Scholar 

  101. Phase III Randomized Study of Docetaxel and Prednisone With Versus Without Bevacizumab in Patients With Hormone-Refractory Metastatic Adenocarcinoma of the Prostate (Accessed August 11, 2007, at http://www.cancer.gov/clinicaltrials/CALGB-90401.).

  102. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69 Suppl 3:25–33.

    Article  PubMed  CAS  Google Scholar 

  103. Skillings J, Johnson, DH, Miller, K, Kabbinavar, F, Bergsland, E, Holmgren, E, Holden, SN, Hurwitz, F, Scappaticci, F. Arterial thromboembolic events in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab with chemotherapy. J Clin Onc 23(16 S), 2005: 3019.

    Google Scholar 

  104. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91(3):173–80.

    Article  PubMed  CAS  Google Scholar 

  105. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354(9):980–2; discussion −2.

    Article  PubMed  CAS  Google Scholar 

  106. Fakih MG, Lombardo JC. Bevacizumab-induced nasal septum perforation. Oncologist 2006;11(1):85–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Branch Center for Cancer Research, National Cancer Institute, 20892, Bethesda, MD, USA

    Jeanny B. Aragon-Ching, Ravi A. Madan & James L. Gulley

Authors
  1. Jeanny B. Aragon-Ching
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ravi A. Madan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James L. Gulley
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

    William D. Figg

  2. Department of Surgery Harvard Medical School and Vascular Biology Program, Children's Hospital Boston, Boston, MA, USA

    Judah Folkman

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Aragon-Ching, J.B., Madan, R.A., Gulley, J.L. (2008). The Clinical Utility of Bevacizumab. In: Figg, W.D., Folkman, J. (eds) Angiogenesis. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-71518-6_33

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-71518-6_33

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-71517-9

  • Online ISBN: 978-0-387-71518-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation